| 1 |
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial
Richard Spostol, Inta J. Ertel, R. D. T. Jenkin et al. · Journal of Neuro-Oncology
|
Jul 1989 |
369 |
| 2 |
Acute Graft Versus Host Disease: A Comprehensive Review
Samah Nassereddine, Hind Rafei, Ehab El-Bahesh et al. · Anticancer Research
Open access |
Apr 2017 |
191 |
| 3 |
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas Buckner Johnson et al. · JCI Insight
Open access |
19 Dec 2018 |
165 |
| 4 |
Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis
Robert C.G. Martin, Charles Raben Scoggins, Marshall T. Schreeder et al. · Cancer
|
6 Jul 2015 |
156 |
| 5 |
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer
Mark A. Socinski, Corey Jay Langer, Isamu Okamoto et al. · Annals of Oncology
Open access |
2 Nov 2012 |
108 |
| 6 |
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma
Brian Z. Ring, Robert S. Seitz, Rodney A. Beck et al. · Modern Pathology
Open access |
8 May 2009 |
92 |
| 7 |
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Alexander Lunning, Julie Marie Vose, Loretta J. Nastoupil et al. · Blood
Open access |
26 Sep 2019 |
87 |
| 8 |
Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al. · Haematologica
Open access |
5 May 2016 |
83 |
| 9 |
Immune-based Therapies for Non-small Cell Lung Cancer
Hind Rafei, Ehab El-Bahesh, Antoine Nafez Finianos et al. · Anticancer Research
Open access |
10 Feb 2017 |
82 |
| 10 |
Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial
Robert C.G. Martin, Charles Raben Scoggins, Dana R. Tomalty et al. · Journal of Gastrointestinal Surgery
|
23 Apr 2012 |
76 |
| 11 |
Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley et al. · Blood
Open access |
14 Mar 2015 |
75 |
| 12 |
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity
Devalingam Mahalingam, Judy S. Wang, Erika Paige Hamilton et al. · Clinical Cancer Research
|
28 Feb 2019 |
73 |
| 13 |
A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
Ahmed Sawas, Charles Michael Farber, Marshall T. Schreeder et al. · British Journal of Haematology
Open access |
21 Feb 2017 |
73 |
| 14 |
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
Loretta J. Nastoupil, Matthew Alexander Lunning, Julie Marie Vose et al. · The Lancet Haematology
Open access |
30 Jan 2019 |
72 |
| 15 |
Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer
Corey Jay Langer, Istvan U. Albert, Helen J. Ross et al. · Lung Cancer
|
13 May 2014 |
71 |
| 16 |
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer
Mark A. Socinski, Isamu Okamoto, Jeremy K. Hon et al. · Annals of Oncology
Open access |
10 Jul 2013 |
67 |
| 17 |
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced‐stage nonsmall cell lung cancer
Chandra Prakash Belani, Marshall T. Schreeder, Ronald G. Steis et al. · Cancer
Open access |
24 Sep 2008 |
65 |
| 18 |
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Jeff Porter Sharman, Charles Michael Farber, Daruka Mahadevan et al. · British Journal of Haematology
Open access |
16 Dec 2016 |
62 |
| 19 |
Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer
Khursheed Anwer, FJ Kelly, Christina Chu et al. · Gynecologic Oncology
|
14 Jul 2013 |
62 |
| 20 |
Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network
David Robert Spigel, John Daniel Hainsworth, Lisa K. Simons et al. · Journal of Thoracic Oncology
Open access |
Sep 2007 |
53 |
| 21 |
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
Alberto Chiappori, Marshall T. Schreeder, M. M. Moezi et al. · British Journal of Cancer
Open access |
Feb 2012 |
51 |
| 22 |
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial
Jeff Porter Sharman, Danielle M. Brander, Anthony R. Mato et al. · The Lancet Haematology
|
23 Feb 2021 |
50 |
| 23 |
Axitinib and/or bevacizumab with modified FOLFOX‐6 as first‐line therapy for metastatic colorectal cancer: A randomized phase 2 study
Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn et al. · Cancer
Open access |
19 Apr 2013 |
46 |
| 24 |
Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Jennifer R. Brown, Wael A. Harb, Brian Thomas Hill et al. · Blood
|
15 Nov 2013 |
45 |
| 25 |
Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung Cancer
Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud et al. · Clinical Lung Cancer
|
19 Oct 2016 |
44 |
| 26 |
The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence
David G. Hicks, Bagi R. Janarthanan, Ramya Vardarajan et al. · BMC Cancer
Open access |
22 Mar 2010 |
39 |
| 27 |
Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study
Steven E. Coutre, John Paul Leonard, Richard R. Furman et al. · Blood
|
16 Nov 2012 |
36 |
| 28 |
Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non–Small-Cell Lung Cancer
Vera Hirsh, Isamu Okamoto, Jeremy K. Hon et al. · Journal of Thoracic Oncology
Open access |
17 Dec 2013 |
35 |
| 29 |
The cost of elections: the effects of public sector austerity on electoral integrity and voter engagement
Toby S. James, Tyrone Jervier · Public Money & Management
Open access |
10 Jul 2017 |
34 |
| 30 |
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Jeff Porter Sharman, Sven de Vos, John Paul Leonard et al. · Blood
|
18 Nov 2011 |
32 |
| 31 |
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma
John Daniel Hainsworth, David Robert Spigel, John H. Barton et al. · Cancer
Open access |
9 Jun 2008 |
32 |
| 32 |
TLE3 as a candidate biomarker of response to taxane therapy
Swati Kulkarni, David G. Hicks, Nancy Watroba et al. · Breast Cancer Research
Open access |
23 Mar 2009 |
27 |
| 33 |
Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma
Shaker R. Dakhil, Robert B. Hermann, Marshall T. Schreeder et al. · Leukemia & lymphoma/Leukemia and lymphoma
|
29 Jan 2014 |
25 |
| 34 |
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer
Patricia Rich et al. · Journal for ImmunoTherapy of Cancer
Open access |
Oct 2021 |
22 |
| 35 |
Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
Sven de Vos, Nina D. Wagner‐Johnston, Steven E. Coutre et al. · Blood Advances
Open access |
30 Nov 2016 |
22 |
| 36 |
A Phase 1 Study Of The Selective PI3Kδ Inhibitor Idelalisib (GS-1101) In Combination With Therapeutic Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia
Richard R. Furman, Sven de Vos, John Paul Leonard et al. · Blood
|
15 Nov 2013 |
20 |
| 37 |
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E. Coutre, Ian W. Flinn, Sven de Vos et al. · HemaSphere
Open access |
24 Apr 2018 |
16 |
| 38 |
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.
Ian W. Flinn, Marshall T. Schreeder, Nina D. Wagner‐Johnston et al. · Blood
|
19 Nov 2010 |
16 |
| 39 |
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
Jeff Porter Sharman, Charles Michael Farber, Daruka Mahadevan et al. · Blood
|
6 Dec 2014 |
16 |
| 40 |
Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation
Steven E. Coutre et al. · Blood
|
15 Nov 2013 |
16 |
| 41 |
Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions
Nicholas Mitsiades, Bedoya · OncoTargets and Therapy
Open access |
2013 |
15 |
| 42 |
Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g)
Jennifer R. Brown, Susan Mary O'Brien, C. Daniel Kingsley et al. · Blood
|
15 Nov 2013 |
14 |
| 43 |
Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study
Nathan Hale Fowler, Sven de Vos, Marshall T. Schreeder et al. · Blood
|
16 Nov 2012 |
13 |
| 44 |
Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results
Sven de Vos, Nina D. Wagner‐Johnston, Steven E. Coutre et al. · Blood
|
6 Dec 2014 |
13 |
| 45 |
Chemo-Immunotherapy Combination Of Idelalisib With Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability
Jacqueline C. Barrientos, Nina D. Wagner‐Johnston, Sven de Vos et al. · Blood
|
15 Nov 2013 |
13 |
| 46 |
Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Jacqueline C. Barrientos, Steven E. Coutre, Sven de Vos et al. · Blood
|
6 Dec 2014 |
13 |
| 47 |
Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer
Johanna C. Bendell, Heinz‐Josef Lenz, Theresa M. Ryan et al. · Investigational New Drugs
|
2 Apr 2014 |
13 |
| 48 |
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)
Sven de Vos, Marshall T. Schreeder, Ian W. Flinn et al. · Blood
|
18 Nov 2011 |
12 |
| 49 |
A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia
Daruka Mahadevan, Emily K. Pauli, Kathy Cutter et al. · Blood
|
3 Dec 2015 |
12 |
| 50 |
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma
Matthew Alexander Lunning, Julie Marie Vose, Marshall T. Schreeder et al. · Blood
|
6 Dec 2014 |
10 |